{"title":"Immune biomarkers for predicting postoperative pneumonia following hip fracture surgery.","authors":"Zemin Wu, Bing Li, Wenke Zhu, JingJing Shang, Jiapei Yao, Yong Huang, Jiansong Yin, Xindie Zhou","doi":"10.1080/17520363.2025.2491302","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Abnormalities of lymphocyte subsets have been observed in patients with pneumonia. This study investigated the diagnostic efficiency of lymphocyte subsets in the detection of early-stage postoperative pneumonia (POP) among older patients undergoing hip fracture surgery.</p><p><strong>Methods: </strong>A total of 576 patients with hip fracture were recruited and analyzed for lymphocyte subsets on the first postoperative day.</p><p><strong>Results: </strong>The incidence of POP was 10.6% (61/576) from March 2016 to December 2023. The area under the curve for the percentage of CD8+ HLA-DR+ T cells was higher than that of CD4+ T and CD4+ CD45RA+ T cells. A high percentage of CD8+ HLA-DR+ T cells was significantly associated with an increased occurrence of POP. The positive findings remained significant after adjusting for confounding factors. Among the multiple complications, patients with diabetes tended to have higher percentages of CD8+ HLA-DR+ T cells.</p><p><strong>Conclusions: </strong>The percentage of CD8+ HLA-DR+ T cells had a good predictive value for detecting early-stage POP. Multi-center prospective studies with larger sample sizes are needed to verify this finding.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":"19 9","pages":"341-348"},"PeriodicalIF":1.9000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051530/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2491302","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/13 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Abnormalities of lymphocyte subsets have been observed in patients with pneumonia. This study investigated the diagnostic efficiency of lymphocyte subsets in the detection of early-stage postoperative pneumonia (POP) among older patients undergoing hip fracture surgery.
Methods: A total of 576 patients with hip fracture were recruited and analyzed for lymphocyte subsets on the first postoperative day.
Results: The incidence of POP was 10.6% (61/576) from March 2016 to December 2023. The area under the curve for the percentage of CD8+ HLA-DR+ T cells was higher than that of CD4+ T and CD4+ CD45RA+ T cells. A high percentage of CD8+ HLA-DR+ T cells was significantly associated with an increased occurrence of POP. The positive findings remained significant after adjusting for confounding factors. Among the multiple complications, patients with diabetes tended to have higher percentages of CD8+ HLA-DR+ T cells.
Conclusions: The percentage of CD8+ HLA-DR+ T cells had a good predictive value for detecting early-stage POP. Multi-center prospective studies with larger sample sizes are needed to verify this finding.
期刊介绍：
Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory.
Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice.
As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications.
Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest.
Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
